{
    "organizations": [],
    "uuid": "147d544bc2ce382c6440587ddfa8e30b12da6d23",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-spark-therapeutics-to-begin-progra/brief-spark-therapeutics-to-begin-program-in-pompe-disease-idUSL1N1P31QD",
    "ord_in_thread": 0,
    "title": "BRIEF-Spark Therapeutics To Begin Program In Pompe Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Spark Therapeutics:\n* SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE\n* SPARK CEO SAYS EXPECTS LUXTURNA GENE THERAPY TO BE AVAILABLE TO PATIENTS IN EUROPE IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)\n ",
    "published": "2018-01-09T07:29:00.000+02:00",
    "crawled": "2018-01-09T16:59:36.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "spark",
        "therapeutic",
        "spark",
        "therapeutic",
        "ceo",
        "say",
        "plan",
        "begin",
        "program",
        "pompe",
        "disease",
        "spark",
        "ceo",
        "say",
        "expects",
        "luxturna",
        "gene",
        "therapy",
        "available",
        "patient",
        "europe",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "bill",
        "berkrot"
    ]
}